Early results of a "First‐in‐Human" Phase 1 clinical study of intracerebroventricular injections of ex vivo expanded, autologous, Wnt‐activated, adipose‐derived stem cells in participants with mild to moderate Alzheimer's Disease (AD)

This "first-in-human" trial of intracerebroventricular injection of expanded autologous, Wnt-expressing, adipose tissue-derived stem cells proved well-tolerated and safe for the low-dose and medium dose cohorts. Secondary endpoints showed promising improvements.